Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

NCT06332131 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT06332131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06332131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Observational
Overall status
Active, not recruiting
Start date
January 15, 2025
Completion date
November 30, 2026
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cardiotoxicity, coronary microvascular dysfunction, lung cancer (nsclc)